Given the similar PSMA-PET uptake of tubarial and parotid glands, as well as the previously demonstrated correlation between tubarial gland dose and xerostomia [10], it seems prudent to adopt parotid dose constraints for the tubarial glands until more specific guidelines become available. This evidence concerns the gene FOLH1 and xerostomia.